MRK ▼ -0.9% - Merck & Co., Inc.
$MRK Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium
22-OCT-2026 03:01 PM ET
Share this post
More filings for $MRK
MRK ▼ -0.9% - Merck & Co., Inc.Oct 22, 2026MRK ▼ -2.3% - Merck & Co., Inc.Oct 22, 2026MRK ▼ -0.3% - Merck & Co., Inc.Oct 21, 2026MRK ▼ -0.3% - Merck & Co., Inc.Oct 21, 2026MRK ▼ -0.4% - Merck & Co., Inc.Oct 13, 2026MRK ▲ +2.8% - Merck & Co., Inc.Oct 10, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment